As of May 25
| -0.44 / -0.46%|
The 10 analysts offering 12-month price forecasts for Neurocrine Biosciences Inc have a median target of 104.00, with a high estimate of 139.00 and a low estimate of 100.00. The median estimate represents a +10.40% increase from the last price of 94.20.
The current consensus among 11 polled investment analysts is to Buy stock in Neurocrine Biosciences Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.